AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M

AtriCure, Inc.

2022-Q1 EPS reported -$0.33 revenue$74,576,000

Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).
Gross margin 74.5% vs 75.1% YoY; operating loss narrowed to $14.2M from $15.9M.
GAAP net loss $0.33/share; adjusted loss $0.33/share; adj EBITDA loss $4.2M.
FY 2022 rev guidance $318-330M (+16-20%); adj EPS loss $1.07-$1.12.
CEO cites broad-based growth; EPi-Sense adoption, Cryo Nerve Block expansion, EnCompass launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.